N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial.

Schoeps, Vinicius A; Graves, Jennifer S; Stern, William A; Zhang, Li; Nourbakhsh, Bardia; Mowry, Ellen M; Henry, Roland G; Waubant, Emmanuelle

Schoeps, Vinicius A; Graves, Jennifer S; Stern, William A; Zhang, Li; Nourbakhsh, Bardia; Mowry, Ellen M; Henry, Roland G; Waubant, Emmanuelle.

Afiliación

Schoeps VA; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. Electronic address: vinicius.schoeps@ucsf.edu.
Graves JS; Department of Neurosciences, University of California, San Diego, CA, USA.
Stern WA; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Zhang L; Department of Epidemiology, University of California, San Francisco, CA, USA.
Nourbakhsh B; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Mowry EM; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Henry RG; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Waubant E; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.

Contemp Clin Trials ; 122: 106941, 2022 11.

Article en En | MEDLINE | ID: mdl-36182028

Asunto(s)

Esclerosis Múltiple Crónica Progresiva; Esclerosis Múltiple; Fármacos Neuroprotectores; Humanos; Fármacos Neuroprotectores/efectos adversos; Acetilcisteína/efectos adversos; Progresión de la Enfermedad; Esclerosis Múltiple Crónica Progresiva/diagnóstico por imagen; Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico; Método Doble Ciego; Resultado del Tratamiento; Ensayos Clínicos Controlados Aleatorios como Asunto; Ensayos Clínicos Fase II como Asunto

Palabras clave

Clinical trial; N-acetyl cysteine; Primary progressive multiple sclerosis; Secondary progressive multiple sclerosis; oxidative stress

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Contemp Clin Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google